Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors
Authors' conclusion
The development of multiple endocrine abnormalities in patients treated with ICIs is associated with improved survival compared with that of patients with a single abnormality.
Study context
- Population
- Patients who received immune checkpoint inhibitors (ICIs) between 2014 and 2022, DeSC Japanese administrative claims database
- Participants
- 12,978 patients
- Exposure
- Multiple vs single vs no endocrine abnormalities in patients treated with ICIs
- Outcome
- Overall survival (OS)
Methodological detailsadministrative claims database, Endocrine abnormalities defined by hormone replacement therapy (levothyroxine, hydrocortisone, insulin); T1D additionally by disease name and self-injection fees, Adjusted for confounders including number and duration of ICI administrations
- Administrative claims database
- Endocrine abnormalities defined by hormone replacement therapy (levothyroxine, hydrocortisone, insulin); T1D additionally by disease name and self-injection fees
- Adjusted for confounders including number and duration of ICI administrations
Main finding
As reported in the abstract
Mortality (OS)
Adjusted hazard ratio (95% CI)P value
Multiplevs None
0.39(0.28–0.54)
P < 0.01Singlevs None
0.65(0.5–80.72)
P < 0.01Multiplevs Single
0.56(0.39–0.79)
P < 0.01- Kaplan-Meier: better survival with multiple and single endocrine abnormalities than without
- P < 0.01
Observational data: associations, not effects.
Further findings
Prevalence of endocrine abnormalities
- Single endocrine abnormalities
- 12.0%
- Multiple endocrine abnormalities
- 1.4%
- Most common combination: hypothyroidism and adrenal insufficiency
- 1.3%
Original publication
Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors. J Clin Endocrinol Metab. Published 12 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →